ArticleInternational journal of molecular sciences2026
NRF2/SLC7A11/GPX4 Antioxidant Axis Suppression by Camel Milk Whey Protein Sensitizes MCF-7 Breast Cancer Cells to Cisplatin.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance in breast cancer remains a major clinical challenge, fueled by robust antioxidant defenses that neutralize cisplatin-induced oxidative stress through the NRF2/SLC7A11/GPX4 pathway in luminal breast cancer cells. This study examined camel milk whey protein (CMP), a bioactive fraction rich in lactoferrin and antioxidant peptides, as a redox-modulating chemosensitizer to boost cisplatin efficacy in MCF-7 cells while simultaneously assessing treatment selectivity in non-tumorigenic MCF-12A mammary epithelial cells. Cells were treated for 24 h with CMP (at 200 and 600 ng/mL, designated as P1 and P2) and cisplatin (25 µM), both individually and in combination. Cell viability was evaluated via the MTT assay, and the mRNA expression levels of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.